Person: İLHAN, MAHMUT MUZAFFER
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?(2015-10-01) Ilhan, MAHMUT MUZAFFER; Kahraman, Ozlem Timirci; Turan, Saime; Turgut, SEDA; Karaman, Ozcan; Zeybek, Umit; SHUKUROV, Samir; Yaylim, Ilhan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULObjectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved.Publication Metadata only Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey(2015-01-01T00:00:00Z) Tasan, ERTUĞRUL; HANIMOGLU, Hakan; Turgut, SEDA; Ilhan, MAHMUT MUZAFFER; EVRAN, Sevket; KAYNAR, Mehmet Yasar; TAŞAN, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFERGiant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54x40x40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17x12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.Publication Metadata only Polycystic ovary syndrome is associated with P-wave prolongation and increased P-wave dispersion(2013-09-01) ERDOGAN, Ercan; AKKAYA, Mehmet; TURFAN, Murat; BATMAZ, Gonca; BACAKSIZ, AHMET; TASAL, Abdurrahman; Ilhan, Muzaffer; KUL, Seref; SONMEZ, Osman; VATANKULU, Mehmet Akif; Tasan, ERTUĞRUL; BACAKSIZ, AHMET; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRULPublication Metadata only Electrocardiographic and echocardiographic evidence of myocardial impairment in patients with overt hypothyroidism(2013-12-01) ERDOGAN, Ercan; AKKAYA, Mehmet; Bacaksiz, AHMET; TASAL, Abdurrrahman; Ilhan, Muzaffer; KUL, Seref; ASOGLU, Emin; TURFAN, Murat; SONMEZ, Osman; Tasan, ERTUĞRUL; BACAKSIZ, AHMET; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRULPublication Metadata only Esophagus motility in overt hypothyroidism(2014-07-01) Ilhan, MAHMUT MUZAFFER; Arabaci, ELİF; Turgut, SEDA; Karaman, Ozcan; DANALIOGLU, Ahmet; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; ARABACI, ELİF; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULPurpose Gastrointestinal tract is one of the most affected systems in hypothyroidism. Despite decreased esophageal emptying, prolonged esophageal and gastric transit time have been indicated in previous reports, the mechanism of thyroid hormones activity and antibodies on the esophagus motility is not yet fully understood. This study was conducted to evaluate the esophagus motility by manometry in hypothyroid patients.Publication Metadata only Sleep apnea in acromegaly(2013-09-01) Akkoyunlu, MUHAMMED EMİN; Ilhan, MAHMUT MUZAFFER; Bayram, MEHMET; Tasan, ERTUĞRUL; OZCELIK, Hatice; KARAKOSE, Fatmanur; YAKAR, Fatih; Kart, Levent; AKKOYUNLU, MUHAMMED EMİN; İLHAN, MAHMUT MUZAFFER; BAYRAM, MEHMET; TAŞAN, ERTUĞRUL; OKYALTIRIK, FATMANURPublication Metadata only Comparison of Pulse Rate Variability and Heart Rate Variability for Hypoglycemia Syndrome(2016-01-01) Okkesim, Sukru; Celik, Gamze; Yildirim, Mustafa S.; Ilhan, MAHMUT MUZAFFER; Karaman, Ozcan; Tasan, ERTUĞRUL; Kara, Sadik; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRULBackground: Heart rate variability (HRV) is a signal obtained from RR intervals of electro cardiography (ECG) signals to evaluate the balance between the sympathetic nervous system and the parasympathetic nervous system; not only HRV but also pulse rate variability (PRV) extracted from finger pulse plethysmography (PPG) can reflect irregularities that may occur in heart rate and control procedures.